SEARCH

SEARCH BY CITATION

References

  • 1
    Mollison PL. Engelfriet CP, Contreras M. Blood Transfusion in Clinical Medicine, 9th edn. Oxford: Blackwell Scientific Publications, 1993.
  • 2
    Bowman JM, Pollock JM. Failures of intravenous Rh immune globulin prophylaxis: an analysis of the reasons for such failures. Transfusion Medicine Reviews 1987; 1: 101112.
  • 3
    Stern K, Goodman HS, Berger M. Experimental isoimmunization to hemo-antigens in man. J Immunol 1961: 87: 189.
  • 4
    Finn R, Clarke CA. Donohoe WTA, et al. Experimental studies on the prevention of Rh haemolytic disease. Brit Med J 1961; 1: 1486.
  • 5
    Clarke CA, Donohoe WTA, McConnell RB, et al. Further experimental studies on the prevention of Rh haemolytic disease. BritMed J 1963; i: 979.
  • 6
    Freda VJ, Gorman JG, Pollack W. Successful prevention of experimental Rh sensitization in man with an anti-Rh gamma, globulin antibody preparation: a preliminary report. Transfusion 1964; 4: 26.
  • 7
    Freda VJ, Gorman JG, Pollack W. Rh factor prevention of immunization and clinical trial on mothers. Science 1966: 151: 828.
  • 8
    Combined Study. Prevention of Rh-haemolytic disease: results of the clinical trial. A combined study from centres in England and Baltimore. Brit Med J 1966; 2: 907.
  • 9
    Pollack W, Gorman JG, Freda VJ, et al. Results of clinical trials of RhoGAM in women. Transfusion 1968; 8: 151.
  • 10
    Pollack W. Ascari WQ, Kochesky RJ, et al. Studies on Rh prophylaxis. I. Relationship between doses of anti-Rh and size of antigenic stimulus. Transfusion 1971; 11: 333.
  • 11
    WHO. Prevention of Rh sensitization. Technical Report Series 1971; 468..
  • 12
    Bowman JM, Pollock JM. Reversal of Rh immunization. Fact or fancy vox Sang 1984; 47: 209215.
  • 13
    De Silva M, Contreras M, Mollison PL. Failure of passively administered anti-Rh to prevent secondary Rh responses. Vox Sang 1985: 48: 178180.
  • 14
    AABB. Standards, for Blood Banks and Transfusion Services, 15th edn. Arlington , VA : American Association Blood Banks, 1993.
  • 15
    Hughes-Jones NC, Ellis M, Ivona J, Walker W. Anti-D concentration in mother and child in haemolytic disease of the newborn. Vox Sang 1971: 21: 135.
  • 16
    Bowman CJ, Chown B. Lewis M, et al. Rh-immunisation during pregnancy, antenatal prophylaxis. Can Med Assoc J 1978; 118: 623.
  • 17
    Bowman JM. Controversies in Rh prophylaxis. In: GarrattyG, editor. Hemolytic Diseuse of the Newborn. Arlington , VA : American Association Blood Banks, 1984: 6785.
  • 18
    Tovey LAD, Townley A, Stevenson NJ, Taverner J. The Yorkshire antenatal anti-D immunoglobulin trial in primigravidae. Lancet 1983; ii: 244246.
  • 19
    Walker W, Murray S, Russell JK. Stillbirth due to haemolytic disease of the newborn. J Obstet Gynaec Brit Emp 1957; 44: 573.
  • 20
    Clarke CA, Mollison PL. Deaths from Rh haemolytic disease of the fetus and newborn, 1977–87. J Roy Coll Phycns 1989: 23: 181184.
  • 21
    Hussey R, Clarke CA. Deaths from Rh haemolytic disease in England and Wales in 1988 and 1989. Brit Med J 1991; 303: 445446.
  • 22
    Walker RH. Relevance in the selection of serologic tests for the obstetric patient. In: GarrattyG. editor. Hemolytic Diseuse of the Newborn. Arlington , VA : American Association Blood Banks, 1984: 173200.
  • 23
    Walker RH, Hartrick MB. Non-ABO clinically significant erythrocyte alloantibodies in Caucasian obstetric patients. Transfusion 1991; 31 (Suppl.): 52s (Abstract).
  • 24
    Walker RH, Batten DG, Morrison MM. The current rarity of Rh D hemolytic disease of the newborn in a community hospital. Amer J Clin Path 1993; 100: 340341.